We previously showed that an angiotensin-converting enzyme inhibitor (captopril) or an angiotensin receptor blocker (losartan) reduced infarct size and improved endothelial function in a rat model of ischaemia-reperfusion. The present study was undertaken to see if aspirin (ASA) antagonised the beneficial effects of captopril or losartan.
Introduction
The renin-angiotensin system (RAS) plays an important role in the regulation of cardiovascular function. The primary active peptide hormone of this system is angiotensin II (Ang II). Angiotensinconverting enzyme (ACE) converts angiotensin I (Ang I) to Ang II and also inactivates bradykinin. [1] [2] [3] Our previous studies showed that pre-treatment with either an ACE inhibitor (ACE-I) (captopril) or an angiotensin receptor blocker (ARB) (losartan) for several weeks reduced myocardial infarct (MI) size in a rat model of ischaemia-reperfusion. This treatment also improved endothelial function and reduced atherosclerosis in a rabbit model of atherosclerosis. [4] [5] [6] We also showed that aspirin (ASA) inhibited platelet activity, but did not attenuate experimental atherosclerosis. 7 Many patients with coronary artery disease take ASA to prevent MI, and RAS blockers such as captopril or losartan to lower blood pressure (BP), treat heart failure, and improve endothelial function. There is some evidence, however, that ASA may decrease the effectiveness of ACE-Is, by inhibiting the enzyme cyclooxygenase, which in turn decreases the production of vasodilating prostaglandins such as prostacyclin. 8 In some clinical studies 8, 9 the effects of ACE-Is, but not ARBs, have been attenuated by the concomitant administration of ASA, which presumably reduces the production of vasodilating prostaglandins and bradykinin that are responsible for some of the effects of ACE-Is.We hypothesised that ARBs might not be affected by ASA in the same way.
Thus, the objective of this investigation was to explore the comparative effects of pre-treatment for six weeks with ASA and/or ACE-I (captopril), ARB (losartan), on MI size, haemodynamics, effective refractory period (ERP), ventricular fibrillation threshold (VFT), and endothelial function in a rat model of ischaemia-reperfusion.
Methods

Experimental groups
One hundred and fourteen female Sprague-Dawley rats (body weight 225-250 g) were randomly divided into six groups: group N was a normal control; group A was given 40 mg/kg of ASA in drinking water for six weeks; group C was given 40 mg/kg/day of captopril in drinking water
for six weeks; group L was given 40 mg/kg/day of losartan in drinking water for six weeks; group AC was given 40 mg/kg each of ASA and captopril in drinking water for six weeks; group AL was given 40 mg/kg each of ASA and losartan in drinking water for six weeks. The rats were housed in a room maintained at a constant temperature and kept on a 12-hour light-dark cycle. All rats were fed a regular diet.
ASA, Ang I and II levels
After six weeks, rats in the six groups (six rats selected at random from each group) were sacrificed by lethal intraperitoneal (i.p.) injection with pentobarbital (130 mg/kg). At the time of death, blood was taken for measurement of ASA, Ang I and Ang II. The serum salicylate level was measured with a Du Pont automatic clinical analyser (Du Pont Co.,Wilmington Del.). 7 Plasma Ang I and Ang II were measured by radioimmunoassay. Plasma renin activity (PRA) was measured using an Ang I antibody, expressed as ng of Ang I generated per ml plasma during a 2-hour incubation at 370°C and pH 6.5. Ang II concentration was measured after extraction on bentonite. Recovery of Ang II was 80%. 10, 11 Rat model of acute myocardial ischaemia and reperfusion A rat model of left coronary artery occlusion and reperfusion was used as previously described. 12 After induction of anaesthesia (pentobarbital 40 mg/kg body weight i.p.), a tracheostomy was performed and the animal was ventilated on a Harvard Rodent Respirator (Model 683, Harvard Apparatus). A reversible coronary artery snare occluder was placed around the proximal left anterior descending coronary artery (LAD) through a midline sternotomy. Thirteen rats in each group were subjected to 17 minutes of LAD occlusion and 120 minutes of reflow. A plastic catheter (PE50) was inserted into the femoral artery to measure haemodynamics. Heart rate (HR), systolic BP (SBP), and diastolic BP (DBP) were monitored by a MacLab/4S (Milford, MA).
ERP, VFT and bleeding time
Electrocardiograms (ECGs, lead I or II) were obtained by subcutaneously inserting needle electrodes into the limbs, and were monitored during the occlusion and reperfusion period. After 1 hour of reperfusion, electrodes were inserted into the right ventricular surface about 1 mm deep. ERP measurements were obtained using eight of S1 (100 mS) and followed by one of S2 (from 80 mS) stimuli, with gradual shortening of the S1-S2 period. ERP was assessed as the period (S1-S2) at which there was no response to the S2 stimulus. Subsequently, multiple electrical stimuli (50/second for 2 seconds) were applied and intensified by 0.1 mA each time, using a Stimulator (Model DTU, Bloom Associates, LTD, Reading, PA). VFT was defined as the electrical intensity which induced VF. Determination of bleeding times (BT) was performed by warming the rat tail for 3 minutes in a normal saline solution bath maintained at a temperature of 37°C. The tail was removed from the bath, and a stainless steel blade was used to make a standard 0.5 cm longitudinal prick in the tail; macroscopically obvious vessels were avoided. The incised tail was then immediately placed into a saline bath, which was gently agitated with a magnetic stirrer. BT was taken as the time required for blood flow in the incision to cease. 13 No rat received antiarrhythmics before or during the occlusion and reperfusion.
Infarct size
Infarct size was measured as described previously. 4, 12 The left coronary artery was reoccluded, and phthalocyanin blue dye was injected into the left ventricular (LV) cavity, allowing normally-perfused myocardium to stain blue. The heart was then excised, rinsed of excess dye and sliced transversely from apex to base into 2 mm-thick sections. The sections were incubated in a 1% solution of triphenyltetrazolium chloride (TTC) for 10-15 minutes until viable myocardium was stained brick red. Infarct-related myocardium fails to stain with TTC. The tissue sections were then fixed in a 10% formalin solution and weighed.
Colour digital images of both sides of each transverse slice were obtained with a videocamera (COHU Y/C 460 HTYL, 768 x 494 array, Leica), connected to a microscope (Stereo Zoom 6 Photo, Leica), using the Rasterops Frame Grabber card and Frame Grabber 3.2 software (Rasterops). The regions which were blue-stained (non-ischaemic), red-stained (ischaemic but non-infarcted) and unstained (infarcted) tissue were outlined on each colour image and measured, using the programme NIH Image 1.59 (National Institutes of Health), in a blinded fashion. On each side, the fraction of the LV area representing infarct-related tissue (average of two images) was multiplied by the weight of that section to determine the absolute weight of infarct-related tissue. The infarct size for each heart was expressed as:
Infarct size as a percentage of risk area was then calculated as
Vascular reactivity studies
Aortic ring segments (1-2 mm in diameter and 4-5 mm in length) of six rats in each group were rapidly excised from the descending thoracic aorta for organ bath studies of vascular reactivity. Each ring was suspended horizontally between two parallel stainless steel wires to measure isometric force in individual organ baths containing Krebs solution at 370°C. Isometric force generated by the ring segment was recorded continuous- ly as previously described. 14 Ring segments were stabilised at 1 g rest force for 60 minutes before being studied. Phenylephrine (Phe) in increasing doses from 10 -9 to 10 -4 mol/L was added to each organ bath. For each ring, the dose needed to achieve half-maximal contraction (EC50 Phe ) was calculated. After the Phe contraction series, the baths were washed out three times with fresh Krebs solution and each ring allowed to stabilise for 1 hour. For determination of endothelium-derived nitric oxide (NO)-mediated vasorelaxation, aortic rings that had been precontracted with the EC50 Phe were then exposed to acetylcholine (10 -9 to 10 -4.5 mol/L). Acetylcholine induces vasorelaxation by release of NO that is coupled to muscarinic receptor stimulation. For measurement of endothelium-derived NO-mediated vasorelaxation induced by a non-receptor-dependent mechanism, aortic rings were exposed to a calcium ionophore (A23187) in increasing concentrations (from 10 -9 to 10 -4.5 mol/L) after the rings had been precontracted by EC50 Phe and stable tension had developed. Lastly, each ring was precontracted and exposed to the endothelium-independent relaxation agent nitroglycerin (concentrations from 10 -9 to 10 -5 mol/L).
Statistical analysis
All results are presented as mean+SEM. The response to Phe was expressed as the change in force from baseline (grams). Relaxation of aortic rings is expressed as the percentage change of net developed force ([measured force -baseline force] / [precontracted force -baseline force]). The five treatment groups (ASA,C,L,AC, AL) were compared with the normal control group using one-way analysis of variance (ANOVA) with the regression equation for multiple group comparison. The groups were also compared by two-way analysis of variance for interactions between ASA and ACE-I/ARB. All computations were done with the general linear model procedure in Minitab, version 7.2 (Minitab Statistical Software) or Prime of Biostatistics: The programme, version 3.03 (McGraw-Hill). Statistical significance was set at p<0.05.
Results
Haemodynamic data
There were no significant differences in HR, SBP, DBP, and rate-pressure product (an index of myocardial oxygen consumption) between the six groups at baseline, during coronary occlusion, or during reperfusion, as displayed in Table 1 . The haemodynamic parameters in all rats gradually declined during the course of the experiment.
ASA, Ang I and II levels
After six weeks of pre-treatment, serum salicylate levels in the groups A, AL, and AC were 0.5, 0.6 and 1.1 mg/dl, respectively. Rats treated with losartan for six weeks had significantly higher plasma levels of Ang II and Ang I (111+32 vs. 18+4 pg/ml, p=0.043; 345+110 vs. 55+9 ng/ml, p=0.007). Rats treated with captopril for six weeks had higher levels of plasma Ang I (199+44 vs. 55+9 ng/ml, p=0.049).
ERP, VFT and BT
The ERPs after 1 hour of reperfusion were significantly higher in the groups L,AC,AL and C compared with the control group N ( Table 2 ).The VFT after 1 hour of reperfusion was significantly higher only in group L, as displayed in Table 2 . BTs were significantly higher in the groups A,AC, and AL (Figure 1 ).
Myocardial infarct size
Infarct size (infarct mass/risk area[%]) was significantly smaller in the groups AC, C and L compared with the control group N (Figure 2 ). Using infarct PAPER Figure 2 . There was no interaction between ASA and captopril/losartan by two-way analysis of variance (p=0.537, p=0.311 respectively).
Vascular reactivity
ASA supplementation significantly decreased maximal acetylcholine-induced endotheliumdependent vasorelaxation induced by acetylcholine (-29+8 vs. -69+11%, p<0.01). However, ASA did not decrease vasorelaxation in the AC and AL groups, as displayed in Figures 3 and 4 . Losartan increased endothelium-dependent vasorelaxation induced by A23187 when compared with the ASA group (-97+12 vs. -64+8%, p=0.058). There were no significant differences in maximal endothelium-independent vasorelaxation induced by nitroglycerin among the six groups.
Discussion
The primary findings of this study were that captopril and losartan had cardioprotective effects PAPER which were not attenuated by ASA in this rat model of ischaemia-reperfusion.The results show that: 1) haemodynamic data were not different in the six groups; 2) rats treated with ASA had higher salicylate levels and longer bleeding times; 3) rats treated with captopril or losartan had higher plasma levels of Ang I or Ang I and II, respectively; 4) captopril and losartan increased ERP, even with ASA; 5) captopril and losartan reduced infarct size, even with ASA; 6) ASA decreased endothelium-dependent vasorelaxation, but did not alter the effects of captopril or losartan.
Optimal dose and haemodynamics
It is possible that the results of this study were influenced by the dose of drugs used. We attempted to use a dose that was effective but did not induce hypotension. In our previous rat studies, 40 mg/kg/day of captopril or losartan for six weeks was selected to avoid significant changes in haemodynamics. 4, 6 Also, 40 mg/kg/day of ASA was selected based on previous studies. 7 In the present study, 40 mg/kg/day of captopril or losartan for six weeks only slightly decreased systolic arterial pressure. However, there were no significant differences in haemodynamics between the six groups at any time point during the 17 minutes of ischaemia and 2 hours of reperfusion. Therefore, we conclude that captopril or losartan reduced infarct size independent of haemodynamic effects.
Myocardial infarct size
The ACE-I, captopril reduced infarct size in this rat model of ischaemia-reperfusion. This might suggest that elevated bradykinin and NO play a pivotal role. However, since losartan also reduced infarct size, bradykinin cannot be the only mechanism of benefit. Reducing the adverse effects of Ang II must also be important. Some clinical studies have shown that aspirin reduces infarct size and increases the frequency of non-Q-wave MI. 15 Recent aspirin use was associated with smaller infarct size and fewer Q-wave infarctions among the early survivors of acute MI who did not receive thrombolytic therapy. 16 One rat study showed that aspirin enhances the benefit of late coronary artery reperfusion on infarct shape after 8 hours of coronary occlusion. These beneficial effects are related to increased patency of the microvessels in the infarcted area. 17 The present study showed that ASA reduced infarct size as measured by infarct mass/LV mass (%). ASA with captopril also reduced infarct size as measured by infarct mass/risk area (%) and infarct mass/LV mass (%). ASA with losartan also reduced infarct size (infarct mass/LV mass [%]).
ERP and VF threshold
Ischaemia-reperfusion injury is associated with expansion of the infarction area and the occur-rence of life-threatening arrhythmias. In isolated perfused rat hearts, ACE-Is decreased cardiac enzymes and the incidence of ventricular fibrillation. 18 These effects of ACE-Is have been attributed to both blockade of Ang II synthesis and a decrease in breakdown of bradykinin, which may stimulate the production of prostaglandin and NO. Using Ang II type 1a receptor (AT 1a )-knockout mice, one study found that during ischaemia and reperfusion, Ang II is involved in the induction of ventricular arrhythmias through AT 1 -receptors; both genetic deletion of the AT 1a gene and treatment with the AT 1 -receptor antagonist, CV-11974, significantly attenuated reperfusion arrhythmias. 19 The results in the present study are consistent with the above studies. Captopril or losartan and ASA with captopril or with losartan significantly increased ERP. Losartan increased the threshold of VF during reperfusion. Both captopril and losartan may also suppress the release of catecholamines, and decrease calcium overload. Aspirin did not attenuate the antiarrhythmic effects of captopril and losartan.
Endothelial function
Hypertension is associated with endothelial dysfunction. A study in spontaneously hypertensive rats showed that both captopril and losartan improved endothelial function in aortic rings, not only by enhancing endothelium-dependent relaxation, but also by reducing contractions in response to endothelium-derived contracting factor. 20 Chronic treatment with captopril partially normalised endothelium-dependent relaxation responses in the rat aorta. 21 Some clinical studies showed that aspirin improved endothelial dysfunction in hypercholesterolaemia or atherosclerosis 22, 23 and low-dose aspirin improved endothelial function in hypertensive patients. 24 In contrast, aspirin significantly decreased endotheliumdependent vasorelaxation in our study, although it did not attenuate the effects of captopril or losartan. In the present study, a dose of 40 mg/kg/day per rat corresponds to a human dose of 2,800 mg/day in a 70 kg individual. When using a low dose of ASA (about 100 mg/day), aspirin only inhibits the vasoconstrictor thromboxane A2. However, at higher doses aspirin inhibits both thromboxane A2 and the vasodilator prostacyclin.
Interaction between ASA and ACE inhibitors
Several studies have reported an interaction between ASA and ACE-Is in patients with chronic heart failure, hypertension, acute MI, and chronic coronary artery disease. [25] [26] [27] Aspirin combined with ACE-Is in patients with coronary artery disease was associated with an increased risk of death compared with aspirin alone. 28 Combining aspirin with ACE-Is was associated with higher early readmission rates than use of ACE-Is alone, particularly in patients with depressed ejection fraction and in those without coronary artery disease. 29 There is only weak evidence of any reduction in the benefit of ACE-I therapy when aspirin is added. 30 
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However, some clinical studies showed that ASA does not decrease the mortality benefit at six weeks of ACE-I after acute MI, nor does it increase the risk of major adverse events. 31 ASA had no effect on the vasodilator response to bradykinin and substance P in patients with heart failure treated with an ACE-I. 32 For older (65 years and above) patients with heart failure, aspirin did not appear to negatively affect outcomes, 33 and both ASA and ACE-Is were associated with a slightly lower risk of mortality than those reported for ASA or an ACE-I alone. 34 Both ASA and ACE-Is are beneficial in acute MI. Results support the early (first five weeks) use of an ACE-I after acute MI, irrespective of whether or not ASA was given. 35, 36 The results in the present study are consistent with the above studies.
The dose of aspirin may be important for the interaction between ASA and ACE-I. There is evidence that ASA, at a daily dose of 80-100 mg, prevents the synthesis of thromboxane A2 by platelets, while relatively sparing the synthesis of prostacyclin in the vascular endothelium. Aspirin at a daily dose of 325 mg has significant inhibitory effects on prostacyclin synthesis. 37 There is no evidence of an interaction between ACE-Is and lowdose (75-160 mg/day) ASA on LV ejection fraction in patients three months after acute MI. 38 A dry cough is the most common adverse class effect of all ACE-Is that is related to prostaglandins. Lowdose (100 mg/day) ASA was ineffective in suppressing ACE-I-induced cough, whereas intermediate doses (500 mg/day) completely abolished cough. These findings support combined treatment by low-dose ASA and ACE-I as safe and useful. [39] [40] [41] Prospective, double-blind, randomised controlled trials, using mortality as a criterion of assessment, are needed to answer the question of ASA/ACE-I interaction. 37, 42 Interaction between ASA and losartan There is minimal data in the literature on a potential interaction between ASA and losartan. In patients with hypertension who were treated with losartan, 81 to 325 mg ASA had no significant effect on BP. 43 Similarly, the efficacy of losartan in heart failure was not affected by ASA. 44 Losartan does have antiplatelet effects similar to ASA. 45 Overall, in this study it did not appear that ASA modified the beneficial effects of either captopril or losartan.
Conclusions
Both captopril and losartan show cardiovascular protective effects in a rat model of ischaemiareperfusion. Pre-treatment with either captopril or losartan for six weeks increased the ERP and VF threshold, and reduced MI size. ASA at a high dose caused endothelial dysfunction, but did not attenuate the cardiovascular protective effects of captopril or losartan in this rat model of acute MI. ASA  aspirin  ACE  angiotensin-converting  enzyme  Ang I  angiotensin I  Ang II  angiotensin II  ARB  angiotensin II 
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